U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205900) titled 'A Phase 2 Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus' on Sept. 16.
Brief Summary: This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Obese
Obesity
Intervention:
DRUG: HM15275
HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
DRUG: Placebo of HM15275
A sterile, matching solution supplied in pre-filled syringes.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hanmi Pharmaceu...